Abstract

The YAP–TEAD protein–protein interaction (PPI) mediates the oncogenic function of YAP, and inhibitors of this PPI have potential usage in treatment of YAP-involved cancers. Here we report the design and synthesis of potent cyclic peptide inhibitors of the YAP–TEAD interaction. A truncation study of YAP interface 3 peptide identified YAP<sup>84–100</sup> as a weak peptide inhibitor (IC<sub>50</sub> = 37 μM), and an alanine scan revealed a beneficial mutation, D94A. Subsequent replacement of a native cation−π interaction with an optimized disulfide bridge for conformational constraint and synergistic effect between macrocyclization and modification at positions 91 and 93 greatly boosted inhibitory activity. Peptide <b>17</b> was identified with an IC<sub>50</sub> of 25 nM, and the binding affinity (<i>K</i><sub>d</sub> = 15 nM) of this 17mer peptide to TEAD1 proved to be stronger than YAP<sup>50–171</sup> (<i>K</i><sub>d</sub> = 40 nM)

    Similar works

    Full text

    thumbnail-image

    Available Versions